Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids | Zendy

Xi Qian | Zendy; Karin Yanagi | Zendy; Anne Kane | Zendy; Nicholas Alden | Zendy; Ming Lei | Zendy; David R. Snydman | Zendy; Richard Vickers | Zendy; Kyongbum Lee | Zendy; Cheleste M. Thorpe | Zendy

Open Access

Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids

Author(s) -

Xi Qian,

Karin Yanagi,

Anne Kane,

Nicholas Alden,

Ming Lei,

David R. Snydman,

Richard Vickers,

Kyongbum Lee,

Cheleste M. Thorpe

Publication year - 2020

Publication title -

ajp gastrointestinal and liver physiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.644

H-Index - 169

eISSN - 1522-1547

pISSN - 0193-1857

DOI - 10.1152/ajpgi.00046.2020

Subject(s) - antibiotics , dysbiosis , clostridioides , bile acid , medicine , vancomycin , gut flora , gastroenterology , clostridium difficile , microbiology and biotechnology , biology , bacteria , immunology , staphylococcus aureus , genetics

This is the first study to demonstrate in humans the relationships between Clostridioides difficile antibiotic treatment choice and bile acid metabolism both during therapy and after treatment cessation. The results show a microbiota- and metabolome-preserving property of a novel narrow-spectrum agent that correlates with the agent’s favorable sustained clinical response rates compared with broad-spectrum antibiotic treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research